Rasayani Biologics Profile
Key Indicators
- Authorised Capital ₹ 1.35 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.33 Cr
as on 11-12-2024
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.37 M
as on 11-12-2024
- Satisfied Charges ₹ 5.37 M
as on 11-12-2024
- Revenue -97.17%
(FY 2020)
- Profit 40.25%
(FY 2020)
- Ebitda 49.88%
(FY 2020)
- Net Worth 17.91%
(FY 2020)
- Total Assets 16.93%
(FY 2020)
About Rasayani Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.35 Cr and a paid-up capital of Rs 1.33 Cr.
The company currently has active open charges totaling ₹5.37 M. The company has closed loans amounting to ₹5.37 M, as per Ministry of Corporate Affairs (MCA) records.
Vineeta Bendale and Yogesh Bendale serve as directors at the Company.
- CIN/LLPIN
U24232PN2007PTC129670
- Company No.
129670
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Rasayani Biologics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vineeta Bendale  | Director | 26-Feb-2007 | Current |
| Yogesh Bendale | Director | 26-Feb-2007 | Current |
Financial Performance of Rasayani Biologics.
Rasayani Biologics Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 97.17% decrease. The company also saw a substantial improvement in profitability, with a 40.25% increase in profit. The company's net worth Soared by an impressive increase of 17.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rasayani Biologics?
In 2020, Rasayani Biologics had a promoter holding of 50.44% and a public holding of 49.57%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Department Of Biotechnology Creation Date: 09 Feb 2012 | ₹5.37 M | Open |
Biotechnology Industry Research Assistance Council (Birac) Creation Date: 01 Jan 2014 | ₹5.37 M | Satisfied |
How Many Employees Work at Rasayani Biologics?
Rasayani Biologics has a workforce of 1 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rasayani Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rasayani Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
